News & Media

" "

April 8, 2020

U.S. Supreme Court Upholds Nitric Oxide Patent Win for Linde; Linde Commits to Support Inhaled Nitric Oxide Clinical Studies Relating to COVID-19

Guildford, UK, April 8, 2020 - Linde (NYSE:LIN; FWB:LIN), a leading global supplier of inhaled nitric oxide, is pleased with the decision by the U.S. Supreme Court declining to review the 2019 appeals court decision that affirmed Praxair Distribution, Inc.'s (PDI) right to sell a generic form of inhaled nitric oxide. This decision ends the long-running U.S. patent litigation with Mallinckrodt plc, and affirms the ability of PDI, a wholly owned subsidiary of Linde, to continue supplying inhaled nitric oxide. This drug product is widely used as approved in the U.S. and other countries to improve oxygenation of certain groups of patients.

Business News

“ “

February 10, 2020

Linde Leverages Combined Technology Portfolio to Sign 30 Small On-Site Contracts in its First Year

Guildford, UK, February 10, 2020 - Linde (NYSE:LIN; FWB:LIN) announced today that it has signed three new customer contracts by leveraging legacy Linde and Praxair technologies, made possible following the merger of the two companies. Local business teams have used both companies' legacy technology and applications to approach new customers and offer compelling new solutions to existing customers.

Business News

Stay Up To Date

Sign up to receive Linde share price, news and regulatory filing alerts.
Register here